Preclinical ADME Tox Contract Research

Apredica provides preclinical contract testing services for the evaluation and optimization of the ADME, Toxicity, and Pharmacokinetic properties of drug candidates early in the drug-discovery process. We also provide in vitro testing services for cosmetics, agrochemicals, and other products for REACH compliance.

NEWS: Apredica Acquired by Cyprotex

August 6, 2010. Apredica has been acquired by UK-based ADME CRO Cyprotex. Read more.

NEWS: Apredica Acquires Cellumen Assets

August 4, 2010. Apredica has acquired the intellectual property for offering the Cellular Systems Biology (CSB™) and High Content Toxicology services developed and commercialized by Cellumen, Inc. Read more.

Why Apredica for Preclinical ADME Tox?

• Trusted for Quality
  In 2009 Apredica did 265 customer studies. 81% of our business was from repeat customers. 29% of our new customers came from referrals. More about our clients.


• Scientist-to-Scientist Communications
  All accounts are served by Scientist Study Managers working in the lab on your ADME Tox research.


• Fast Turnaround
  ADME Tox results in just days. Courier pickup in Cambridge and greater Boston.


• Service-Focused CRO - No Internal Drug-Discovery Program
  The only drug-discovery programs Apredica advances are those of our clients.


• Drug-Discovery Expertise - High Ph.D. Ratio
  Apredica's scientists each have more than 10 years' drug-discovery experience. 80% have Ph.D.s. This allows us to customize work to fit clients' needs.

Contact us to discuss how Apredica's ADME Tox testing services can help your organization increase the speed of drug discovery while reducing costs. Ask about Apredica's ADDME^sm approach for Avoiding Drug Development Mistakes Early.

See our parody of ADME Tox oversights in drug development.